CA2008263A1 - Derives de la pyrazolopyridine et methode de preparation - Google Patents

Derives de la pyrazolopyridine et methode de preparation

Info

Publication number
CA2008263A1
CA2008263A1 CA2008263A CA2008263A CA2008263A1 CA 2008263 A1 CA2008263 A1 CA 2008263A1 CA 2008263 A CA2008263 A CA 2008263A CA 2008263 A CA2008263 A CA 2008263A CA 2008263 A1 CA2008263 A1 CA 2008263A1
Authority
CA
Canada
Prior art keywords
compounds
processes
preparation
infarction
pyrazolopyridine compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2008263A
Other languages
English (en)
Other versions
CA2008263C (fr
Inventor
Youichi Shiokawa
Atsushi Akahane
Takafumi Mitsunaga
Hirohito Katayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2008263A1 publication Critical patent/CA2008263A1/fr
Application granted granted Critical
Publication of CA2008263C publication Critical patent/CA2008263C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002008263A 1989-01-23 1990-01-22 Derives de la pyrazolopyridine et methode de preparation Expired - Fee Related CA2008263C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898901423A GB8901423D0 (en) 1989-01-23 1989-01-23 Pyrazolopyridine compound and processes for preparation thereof
GB8901423.7 1989-01-23

Publications (2)

Publication Number Publication Date
CA2008263A1 true CA2008263A1 (fr) 1990-07-23
CA2008263C CA2008263C (fr) 2000-03-14

Family

ID=10650453

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002008263A Expired - Fee Related CA2008263C (fr) 1989-01-23 1990-01-22 Derives de la pyrazolopyridine et methode de preparation

Country Status (23)

Country Link
US (1) US4985444A (fr)
EP (1) EP0379979B1 (fr)
JP (2) JPH0794454B2 (fr)
KR (1) KR0159502B1 (fr)
CN (1) CN1031570C (fr)
AT (1) ATE150462T1 (fr)
AU (1) AU628913B2 (fr)
CA (1) CA2008263C (fr)
DE (1) DE69030206T2 (fr)
DK (1) DK0379979T3 (fr)
ES (1) ES2098229T3 (fr)
FI (1) FI96205C (fr)
GB (1) GB8901423D0 (fr)
GR (1) GR3023219T3 (fr)
HU (2) HUT53368A (fr)
IE (1) IE900161L (fr)
IL (1) IL93050A (fr)
NO (1) NO176356C (fr)
PH (1) PH30968A (fr)
PT (1) PT92935B (fr)
RU (1) RU2007403C1 (fr)
UA (1) UA43821C2 (fr)
ZA (1) ZA90200B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
ATE161178T1 (de) * 1992-06-10 1998-01-15 Fujisawa Pharmaceutical Co Pyrazolpyridine für die behandlung der anämie
AU7546794A (en) * 1993-09-06 1995-03-27 Kyowa Hakko Kogyo Co. Ltd. Depression remedy
CN1046724C (zh) * 1993-12-29 1999-11-24 藤泽药品工业株式会社 吡唑并吡啶化合物、含有它们的药物组合物、及其制法与用途
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
RU2172742C2 (ru) * 1995-12-28 2001-08-27 Пфайзер Инк. Стимуляторы секреции гормона роста
DE69731948D1 (de) * 1996-04-25 2005-01-20 Fujisawa Pharmaceutical Co Mittel zur vorbeugung und heilung ischämischer darmlesion und ileus
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
AU733316B2 (en) * 1996-10-04 2001-05-10 Kyorin Pharmaceutical Co. Ltd. Pyrazolopyridylpyridazinone derivatives and process for preparing the same
EP0972525A4 (fr) * 1997-03-18 2000-11-29 Fujisawa Pharmaceutical Co Medicaments pour la prevention et la therapie de l'hyperphosphatemie
ATE281458T1 (de) * 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
AU754094B2 (en) * 1998-06-01 2002-11-07 Astellas Pharma Inc. Remedies for male sterility
WO1999067239A1 (fr) * 1998-06-22 1999-12-29 Fujisawa Pharmaceutical Co., Ltd. Composes pyrazolopyridiniques et leur utilisation comme medicaments
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
ATE275148T1 (de) 1998-11-03 2004-09-15 Glaxo Group Ltd Pyrazolopyridin derivative als selektive cox-2 inhibitoren
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
WO2000052008A1 (fr) 1999-02-27 2000-09-08 Glaxo Group Limited Pyrazolopyridines
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1377573B1 (fr) * 2000-12-15 2005-07-27 Glaxo Group Limited Derives de pyrazolopyridine
ES2245380T3 (es) * 2000-12-15 2006-01-01 Glaxo Group Limited Pirazolopiridinas.
BR0207096A (pt) * 2001-02-20 2004-01-20 Astrazeneca Ab Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3
US7153855B2 (en) * 2001-03-08 2006-12-26 Smithkline Beecham Corporation Pyrazolopyridinyl pyrimidine therapeutic compounds
WO2002078701A1 (fr) * 2001-03-30 2002-10-10 Smithkline Beecham Corporation Utilisation de pyrazolopyridines comme composes therapeutiques
EP1372643A1 (fr) * 2001-03-30 2004-01-02 Smithkline Beecham Corporation Pyralopyridines, leur procede de preparation et leur utilisation en tant que composes therapeutiques
JP4219171B2 (ja) * 2001-04-10 2009-02-04 スミスクライン ビーチャム コーポレーション 抗ウイルス性ピラゾロピリジン化合物
BR0209252A (pt) * 2001-04-27 2004-07-20 Eisai Co Ltd Pirazolo[1,5-a]piridinas e medicamentos contendo as mesmas
AU2002305143A1 (en) * 2001-04-27 2002-11-11 Smithkline Beecham Corporation Pyrazolo'1,5-a!pyridine derivatives
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
KR20040018281A (ko) * 2001-06-21 2004-03-02 스미스클라인 비참 코포레이션 포진 바이러스 감염의 예방 및 치료를 위한 이미다조[1，２－α]피리딘 유도체
ES2286272T3 (es) * 2001-09-07 2007-12-01 Smithkline Beecham Corporation Pirizolo-piridinas para el tratamiento de infecciones por herpes.
US7244740B2 (en) * 2001-10-05 2007-07-17 Smithkline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
AUPR916301A0 (en) * 2001-11-29 2001-12-20 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
WO2003050120A1 (fr) * 2001-12-11 2003-06-19 Smithkline Beecham Corporation Derives de la pyrazolo-pyridine, agents anti-herpes
US20040021778A1 (en) * 2002-08-05 2004-02-05 Oldani Jerome L. Security system with remote access and control
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
WO2004033454A1 (fr) * 2002-10-03 2004-04-22 Smithkline Beecham Corporation Composes therapeutiques a base de derives de pyrazolopyridine
JP5352452B2 (ja) * 2006-06-06 2013-11-27 メディシノバ， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
KR100809368B1 (ko) * 2006-08-09 2008-03-05 한국과학기술원 성대파를 이용한 음색 변환 시스템
RU2394034C2 (ru) * 2007-04-26 2010-07-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН ПРОИЗВОДНЫЕ 4,6-ДИМЕТИЛ-2,3-ДИГИДРО-1Н-ПИРАЗОЛО[4,3-c]ПИРИДИН-3-ОНОВ И ЭФИРЫ 2,6-ДИМЕТИЛ-4-ФЕНИЛ-ГИДРАЗИНОНИКОТИНОВЫХ КИСЛОТ В КАЧЕСТВЕ ПРОМЕЖУТОЧНЫХ ПРОДУКТОВ ДЛЯ ИХ СИНТЕЗА, ОБЛАДАЮЩИЕ АНТИДЕПРЕССАНТНОЙ И АНКСИОЛИТИЧЕСКОЙ АКТИВНОСТЬЮ
MY152687A (en) 2008-04-15 2014-10-31 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound
US20110039873A1 (en) * 2009-06-08 2011-02-17 Gaeta Federico C A SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
JPWO2011043387A1 (ja) * 2009-10-08 2013-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
WO2011074658A1 (fr) 2009-12-18 2011-06-23 田辺三菱製薬株式会社 Nouvel agent antiplaquettaire
SG11201406759YA (en) 2012-04-26 2014-11-27 Bristol Myers Squibb Co Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
ES2640916T3 (es) 2012-04-26 2017-11-07 Bristol-Myers Squibb Company Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor 4 activados por proteasa (PAR4) para tratar agregación plaquetaria
KR20150003766A (ko) 2012-04-26 2015-01-09 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피리다진 유도체
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention
TWI629982B (zh) * 2013-05-28 2018-07-21 拉夸里亞創藥股份有限公司 多晶型形式
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
ES2707124T3 (es) * 2014-08-05 2019-04-02 Raqualia Pharma Inc Derivados de serina como agonistas del receptor de grelina
MX2021011316A (es) * 2019-03-20 2021-10-13 Goldfinch Bio Inc Piridazinonas y metodos de uso de estas.
WO2022071777A1 (fr) * 2020-09-29 2022-04-07 연세대학교 산학협력단 Composition et procédé pour la prévention ou le traitement d'une maladie respiratoire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
AU556031B2 (en) * 1982-06-16 1986-10-16 May And Baker Ltd. 3-(n,n-dimethylcarbamoyl)pyrazolo(1,5-alpha)-pyridine
FR2601368B1 (fr) * 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
JPS63135381A (ja) * 1986-11-26 1988-06-07 Kyorin Pharmaceut Co Ltd 多剤耐性癌細胞に対する感受性増強剤及びその製造方法
DE3710937A1 (de) * 1987-04-01 1988-10-13 Boehringer Mannheim Gmbh Chromogene verbindungen, ihre herstellung und verwendung als enzymsubstrate
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines

Also Published As

Publication number Publication date
RU2007403C1 (ru) 1994-02-15
FI96205C (fi) 1996-05-27
KR900011773A (ko) 1990-08-01
US4985444A (en) 1991-01-15
NO900306L (no) 1990-07-24
PT92935A (pt) 1990-07-31
CA2008263C (fr) 2000-03-14
EP0379979B1 (fr) 1997-03-19
PT92935B (pt) 1995-12-29
GR3023219T3 (en) 1997-07-30
IE900161L (en) 1990-07-23
JPH0794454B2 (ja) 1995-10-11
GB8901423D0 (en) 1989-03-15
JPH02243689A (ja) 1990-09-27
KR0159502B1 (ko) 1998-12-01
HU211684A9 (en) 1995-12-28
JPH0881465A (ja) 1996-03-26
IL93050A0 (en) 1990-11-05
EP0379979A1 (fr) 1990-08-01
FI900307A0 (fi) 1990-01-19
FI96205B (fi) 1996-02-15
ATE150462T1 (de) 1997-04-15
AU4869690A (en) 1990-07-26
NO176356B (no) 1994-12-12
DE69030206T2 (de) 1997-07-10
UA43821C2 (uk) 2002-01-15
NO176356C (no) 1995-03-22
DE69030206D1 (de) 1997-04-24
IL93050A (en) 1995-05-26
AU628913B2 (en) 1992-09-24
HUT53368A (en) 1990-10-28
DK0379979T3 (fr) 1997-04-07
CN1031570C (zh) 1996-04-17
NO900306D0 (no) 1990-01-22
ZA90200B (en) 1990-10-31
HU900228D0 (en) 1990-03-28
PH30968A (en) 1997-12-23
CN1044656A (zh) 1990-08-15
ES2098229T3 (es) 1997-05-01

Similar Documents

Publication Publication Date Title
CA2047283A1 (fr) Compose a base de pyrazolopyridine et methode de preparation
CA2065644A1 (fr) Compose a base de pyrazolopyridine et methodes de preparation
CA2190087C (fr) Composes nitres et compositions de ceux-ci, possedant des proprietes antti-inflammatoire, analgesique et anti-thrombose
KR100783835B1 (ko) 면역억제제로서 5-(벤즈-(ｚ)-일리덴-티아졸리딘-4-원유도체
EP2948147B1 (fr) Acides phtalamiques n-substitués-5-substitués utilisés en tant qu'inhibiteurs de la sortiline
EP0975597B1 (fr) Derives de quinoleines en tant qu'inhibiteurs de la vih integrase
KR930006027A (ko) 엔케팔리나제 및 안지오텐신 전환 효소(ace)의 억제제로서 유용한 2-치환 인단-2-메르캅토아세틸아미드 유도체
RU95112848A (ru) Гетеробициклические производные сульфонамида и сульфонового эфира, способы получения, антиопухолевое средство, фармакологическая композиция, способ лечения
NO176356C (no) Analogifremgangsmåte for fremstilling av nye terapeutisk aktive pyrazolopyridinforbindelser
KR930004295A (ko) N-아실-n-헤테로사이클릴알킬아미노산, 이의 제조방법, 이를 함유하는 약제학적 조성물 및 이의 용도
CA2681972A1 (fr) Derives d'acide dibenzoique substitues et leur utilisation
HK101187A (en) N-imidazolyl derivatives of bicyclic compounds and process for their preparation
DE60220255T2 (de) N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung
KR900018037A (ko) 치환 (퀴놀린-2-일-메톡시)페닐-아실-술폰아미드 및-시안아미드, 그의 제조 방법 및 약제로서의 용도
JPH0832687B2 (ja) ２，４−および２，５−置換ピリジン−ｎ−オキシド
EP0700911B1 (fr) Dérivés d'imidazole à activité anti-HIV
CA2626451A1 (fr) Derives de l'acide cyclopropylacetique et leur utilisation
JPS6229566A (ja) 新規グアニジノメチル安息香酸誘導体
KR870001144B1 (ko) 삼환 옥스인돌 카복스아미드 유도체의 제조방법
FR2516083A1 (fr) Derives de l'ergoline, procede pour leur preparation et medicaments les contenant
KR100348138B1 (ko) 벤조락탐유도체
US4661514A (en) Pharmaceutical and veterinary compositions for the treatment of ischemic cardiac disorders
JPS62263177A (ja) ベンズイミダゾ−ル化合物
CA2228385A1 (fr) Composes analogues a la thalidomide de la classe comprenant les piperidine-2,6-diones
KR100351884B1 (ko) Il-1작용억제제로서의헤테로시클릭벤젠술포닐이민유도체

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed